France conducts approximately 1,100 clinical trials per year — third in Europe behind Germany (1,800) and the UK (1,600), but ahead of Spain, Italy, and all other EU member states. In global terms, France ranks among the top five countries for clinical trial volume, hosting roughly 6% of all global trials despite representing 1% of global GDP. The clinical research ecosystem is one of France’s most underappreciated industrial assets, generating approximately €6 billion annually in direct economic activity and sustaining 45,000 jobs in the clinical research ecosystem.

France 2030 targets a step-change: by 2027, France aims to reach 1,400+ annual trial starts, move from third to second in Europe by trial volume, and cut the median administrative approval-to-first-patient timeline from 14 months to 9 months. The acceleration program, funded at €300 million, is one of the most operationally complex elements of France 2030 because it requires coordinating regulatory reform, hospital infrastructure investment, and private-sector incentives simultaneously.

The Infrastructure: What France Already Has

France’s clinical trial infrastructure has three primary components, each world-class in different dimensions:

The CHU Network (Centres Hospitaliers Universitaires)

France has 31 university hospital groups (CHUs) that serve as the primary clinical trial sites. The largest — AP-HP (Assistance Publique–Hôpitaux de Paris) with 39 hospitals and 23,000 beds — is the world’s second-largest clinical research institution by patient volume, after the US NIH Clinical Center. AP-HP alone conducts approximately 3,500 clinical studies annually across all phases.

The other major CHU clinical research hubs:

• CHU Lyon (HCL): 350+ annual trials, specialty strength in infectious disease, oncology, and transplantation
• CHU Bordeaux: 280+ annual trials, cardiovascular disease and neurology focus
• CHU Toulouse: 250+ annual trials, rare diseases and genomics
• CHU Nantes: 220+ annual trials, immunology and biotherapy
• CHU Marseille (AP-HM): 200+ annual trials, tropical medicine and pulmonology

The INSERM Clinical Investigation Centers (CIC)

INSERM operates 40 Clinical Investigation Centers embedded within CHU hospitals across France. CICs are dedicated early-phase research units — specifically designed for Phase 1 and Phase 2a trials where intensive monitoring, specialized staff, and rapid patient assessment are critical. France’s CIC network is unmatched in Europe for early-phase capacity.

France 2030 invested €80 million in CIC infrastructure modernization from 2022-2025: new dedicated Phase 1 units at AP-HP Henri-Mondor (oncology), CHU Lyon-Sud (metabolic diseases), and CHU Bordeaux (cardiology). These three sites added capacity for approximately 150 additional early-phase trial patients annually — significant in a market where Phase 1 capacity is a genuine bottleneck.

The ICRIN Network

The Inserm Clinical Research Infrastructure Network (ICRIN) is the coordinating layer of French clinical research — a network of specialist platforms providing shared services to CHU sites: biobanking, data management, pharmacokinetics, genomics, and imaging analysis. ICRIN coordinates with the European Clinical Research Infrastructure Network (ECRIN), allowing French trial sites to participate in European multi-center studies with standardized protocols.

France 2030 funded a €40 million ICRIN upgrade, including:

• Harmonized electronic data capture systems across all 31 CHUs (replaced 11 incompatible legacy systems)
• A national randomization system reducing administrative burden for multi-center French trials
• Central imaging analysis platform at AP-HP for oncology trials (shared with 12 CHU sites)

The Regulatory Bottleneck: France’s Critical Weakness

Despite its infrastructure strengths, France consistently loses clinical trial competitiveness to Germany and the UK on one measure: administrative approval speed. A 2023 EFPIA survey found the median time from protocol submission to first patient enrolled in France was 14.2 months — compared to 11.8 months in Germany, 10.4 months in the UK, and 9.1 months in Spain.

The bottleneck has two components:

Ethics Committee Review: France has 39 Comités de Protection des Personnes (CPPs) — one per administrative region plus specialist committees — responsible for ethical review of clinical protocols. CPPs operate with varying caseloads, staffing levels, and review timelines. The 2022 JARDÉ law reform consolidated some CPPs and created a centralized randomization system for assigning protocols to CPPs. But as of 2025, median CPP review time remains 60-90 days.

ANSM Regulatory Review: The Agence Nationale de Sécurité du Médicament (ANSM, France’s EMA-equivalent national authority) processes clinical trial authorizations for French sites. ANSM’s 30-day legal maximum for Phase 2-3 authorization is generally met, but Phase 1 oncology reviews — which require more intensive safety evaluation — average 45-60 days.

France 2030’s regulatory reform component commits to:

• Reducing CPP review time to maximum 45 days by 2026 (requiring additional CPP staffing funded at €15 million)
• ANSM digital transformation: electronic submission, AI-assisted protocol review, dedicated fast-track for France 2030-funded compounds (target: 15-day authorization)
• Single-submission portal for simultaneous CPP and ANSM applications (launched 2024)

The Rebiomed Initiative: Clinical Research Acceleration

The Rebiomed (Recherche en Biologie et Médecine) program, launched under France 2030 with €200 million in funding, is the operational vehicle for clinical trial acceleration. Its three main components:

Rebiomed-Infrastructure: Hospital infrastructure upgrades at 15 CHUs — dedicated clinical research space, early-phase monitoring units, biobanking capacity. Target: 200 additional Phase 1-2 trial slots per year by 2026.

Rebiomed-Talent: Training program for 1,500 additional clinical research associates (CRAs), data managers, and biostatisticians — addressing the workforce bottleneck that constrains CHU trial capacity. Partnership with 12 French universities offering master’s programs in clinical research.

Rebiomed-Industry: A co-investment scheme where pharmaceutical or biotech companies committing to conduct Phase 2 or Phase 3 trials at French sites receive Bpifrance matching grants of 25% of trial costs (up to €2 million per trial, maximum 3 trials per company). By 2025, 34 trials had enrolled under this scheme, generating €85 million in industry investment and €22 million in France 2030 co-investment.

The UK Post-Brexit Opportunity

Brexit has created a structural opportunity for France that industry insiders discuss privately but rarely publicly. UK pharmaceutical companies and CROs need EU-jurisdiction trial sites for studies requiring EMA regulatory data — UK sites generate data recognized by MHRA but not automatically by EMA. Companies running pan-European trials increasingly need to include substantial EU patient cohorts.

France, with Europe’s third-largest patient population and strongest hospital research infrastructure after Germany, is the natural beneficiary. Between 2021 and 2025, France saw a 12% increase in UK-sponsored clinical trial applications — a meaningful shift in the competitive landscape that France 2030 is actively exploiting through targeted commercial development programs by Bpifrance and the Alliance pour la Recherche et l’Innovation des Industries de Santé (ARIIS).

Key Performance Targets

France 2030 clinical trials targets (baseline 2021 → target 2027):

• Annual trial starts: 1,050 → 1,400+
• European ranking by trial volume: 3rd → 2nd
• Median approval-to-first-patient: 14.2 months → 9 months
• Phase 1 capacity: +200 patients per year
• Industry-sponsored trials with France 2030 co-investment: 50+ by 2027
• CRA/data manager workforce: +1,500 trained professionals

Related: Health Data Hub | France 2030 Health Sector Hub | OSE Immunotherapeutics | Genfit